The companies Pathos AI, Taysha Gene Therapies, and Abeona Therapeutics bagged the biggest biotech funding rounds overall in ...

Which cancer drug developers are attractive takeover targets? We asked Seeking Alpha analysts BioCGT Investor, ALLKA Research and Zach Hartman for their picks. BioCGT Investor: Cardiff Oncology ...

Stocks of cancer treatment developers will be moving into the spotlight later this week when the annual meeting of the ...

While oncology and immuno-oncology companies have always been at the top of acquisition targets, the lucrative obesity sector and gene-editing space are in spotlight as of now. The Zacks ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

“Companies now have a little more confidence ... Shiva Malek, Ph.D., the global oncology chief at Novartis’ Institutes for BioMedical Research, said during a meet the management event in ...

Almost six years on, we're one of the fastest growing oncology companies in the world. We continue to drive forward with this approach supporting patients with cancer in the UK, and around the world.

Accordingly, investing in AI-driven precision oncology companies presents a compelling long-term opportunity for investors. BioXcel: The company expedites the discovery and development of new ...